The estimated Net Worth of Brendan M. O'malley is at least $1.58 Milión dollars as of 25 April 2024. Dr malley owns over 8,600 units of Abeona Therapeutics Inc stock worth over $1,054,934 and over the last 3 years he sold ABEO stock worth over $62,596. In addition, he makes $467,365 as Sr. VP & Gen. Counsel at Abeona Therapeutics Inc.
Dr has made over 8 trades of the Abeona Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 8,600 units of ABEO stock worth $27,864 on 25 April 2024.
The largest trade he's ever made was selling 25,734 units of Abeona Therapeutics Inc stock on 11 October 2021 worth over $23,161. On average, Dr trades about 4,684 units every 47 days since 2021. As of 25 April 2024 he still owns at least 188,718 units of Abeona Therapeutics Inc stock.
You can see the complete history of Dr malley stock trades at the bottom of the page.
Dr. Brendan M. O'Malley J.D., Ph.D. is the Sr. VP & Gen. Counsel at Abeona Therapeutics Inc.
As the Sr. VP & Gen. Counsel of Abeona Therapeutics Inc, the total compensation of Dr D at Abeona Therapeutics Inc is $467,365. There are 1 executives at Abeona Therapeutics Inc getting paid more, with Christine Silverstein having the highest compensation of $1,000,220.
Dr D is 52, he's been the Sr. VP & Gen. Counsel of Abeona Therapeutics Inc since . There are 2 older and 5 younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.
Brendan's mailing address filed with the SEC is 6555 CARNEGIE AVE,, 4TH FLOOR, CLEVELAND,, OH, 44103.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider a Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: